The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding.
Kawai
H
H
Pharmaceuticals Laboratory 1, Yokohama Research Center, Mitsubishi Chemical Corporation, Japan.
Tamao
Y
Y
D000818:Animals; D000991:Antithrombins / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D001760:Bleeding Time; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D007262:Infusions, Intravenous; D008297:Male; D008689:Methacrylates / Q000627:therapeutic use*; D010875:Pipecolic Acids / Q000627:therapeutic use*; D011817:Rabbits; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000991:Antithrombins; D008689:Methacrylates; D010875:Pipecolic Acids; D013449:Sulfonamides; D001120:Arginine; D013917:Thrombin; D013930:Thromboxane-A Synthase; C031942:argatroban; C034364:ozagrel